

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2020

	Shares	Value
COMMON STOCKS[†] - 99.7%		
Biotechnology - 73.7%		
Amgen, Inc.	65,966	\$ 15,558,741
Gilead Sciences, Inc.	171,221	13,173,744
Vertex Pharmaceuticals, Inc.*	40,228	11,678,591
Regeneron Pharmaceuticals, Inc.*	17,336	10,811,596
Illumina, Inc.*	26,443	9,793,165
Biogen, Inc.*	34,304	9,178,035
Seattle Genetics, Inc.*	43,125	7,327,800
Moderna, Inc.*	100,670	6,464,021
Incyte Corp.*	61,920	6,437,822
Alexion Pharmaceuticals, Inc.*	57,241	6,424,730
BioMarin Pharmaceutical, Inc.*	51,946	6,407,020
Corteva, Inc.	224,718	6,020,195
Alnylam Pharmaceuticals, Inc.*	36,760	5,444,524
Exact Sciences Corp.*	55,347	4,811,868
Immunomedics, Inc.*	108,622	3,849,564
Ionis Pharmaceuticals, Inc.*	64,192	3,784,760
Guardant Health, Inc.*	46,098	3,739,931
Exelixis, Inc.*	154,006	3,656,102
ACADIA Pharmaceuticals, Inc.*	72,428	3,510,585
United Therapeutics Corp.*	25,948	3,139,708
Amarin Corporation plc ADR ^{*,1}	432,103	2,990,153
Mirati Therapeutics, Inc.*	25,953	2,963,054
Arrowhead Pharmaceuticals, Inc.*	68,237	2,947,156
Ultragenyx Pharmaceutical, Inc.*	37,580	2,939,508
Acceleron Pharma, Inc.*	30,440	2,900,019
BeiGene Ltd. ADR [*]	14,880	2,803,392
Nektar Therapeutics [*]	117,891	2,730,355
Bluebird Bio, Inc.*	42,451	2,591,209
FibroGen, Inc.*	62,477	2,532,193
Iovance Biotherapeutics, Inc.*	91,690	2,516,890
PTC Therapeutics, Inc.*	46,870	2,378,184
Ligand Pharmaceuticals, Inc. — Class B ^{*,1}	16,101	1,800,897
Intercept Pharmaceuticals, Inc.*	27,643	1,324,376
Myriad Genetics, Inc.*	97,323	1,103,643
Sage Therapeutics, Inc.*	20,116	836,423
Total Biotechnology		176,569,954
Pharmaceuticals - 21.5%		
AbbVie, Inc.	177,919	17,468,088
Horizon Therapeutics plc [*]	82,490	4,584,794
Sarepta Therapeutics, Inc.*	28,479	4,566,323
Neurocrine Biosciences, Inc.*	36,249	4,422,378
Mylan N.V. [*]	239,727	3,854,810
Jazz Pharmaceuticals plc [*]	30,697	3,387,107
PRA Health Sciences, Inc.*	33,491	3,258,339
Alkermes plc [*]	156,156	3,030,207
Agios Pharmaceuticals, Inc.*	49,938	2,670,684
Global Blood Therapeutics, Inc.*	40,813	2,576,525
Portola Pharmaceuticals, Inc.*	87,170	1,568,188
Total Pharmaceuticals		51,387,443
Healthcare-Products - 3.1%		
Bio-Techne Corp.	16,218	4,282,687
Novocure Ltd.*	51,830	3,073,519
Total Healthcare-Products		7,356,206
Healthcare-Services - 1.4%		
Syneos Health, Inc.*	57,610	3,355,783
Total Common Stocks		238,669,386
(Cost \$117,847,106)		
RIGHTS^{†††,2} - 0.0%		
Biotechnology - 0.0%		
Clinical Data, Inc.*	24,000	—
Total Rights		—
(Cost \$—)		
REPURCHASE AGREEMENTS^{††,3} - 0.6%		
Face Amount		
J.P. Morgan Securities LLC issued 06/30/20 at 0.07% due 07/01/20	\$ 856,223	856,223
BofA Securities, Inc. issued 06/30/20 at 0.07% due 07/01/20	354,601	354,601
Barclays Capital, Inc. issued 06/30/20 at 0.07% due 07/01/20	333,324	333,324
Total Repurchase Agreements		1,544,148
(Cost \$1,544,148)		
SECURITIES LENDING COLLATERAL^{†,4} - 1.4%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 0.06% ⁵	3,474,237	3,474,237
Total Securities Lending Collateral		3,474,237
(Cost \$3,474,237)		
Total Investments - 101.7%		\$ 243,687,771
(Cost \$122,865,491)		
Other Assets & Liabilities, net - (1.7)%		(4,045,128)
Total Net Assets - 100.0%		\$ 239,642,643

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at June 30, 2020.

² Security was fair valued by the Valuation Committee at June 30, 2020. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7-day yield as of June 30, 2020.

ADR — American Depositary Receipt
plc — Public Limited Company